28 Years and Going Strong
Trust, focus, and impact are key tenets of our culture. Trust keeps us accountable to ourselves and our partners, and helps foster lasting relationships with people we work with. Focus applies to our discipline and our investment strategy – building small, focused portfolios allows us to keep a high bar, and dedicate more time to each of our investments. Finally, the desire to make a positive impact is why we have spent our careers investing and working in healthcare.
To date, our life science portfolio has produced over 75 FDA approved products. Our tech-enabled services companies treat hundreds of thousands of patients each year. We look forward to what the next generation will bring.
$2.8B
119
77
$36B
ILEX Oncology receives FDA approval for Campath to treat B-Cell Chronic Lymphocytic Leukemia
Cellective Therapeutics acquired by MedImmune
Kosan Bioscience acquired by Bristol-Myers-Squibb
U3 Pharma acquired by Daiichi Sankyo
InterMune Pharmaceuticals acquired by Roche
Swedish Orphan Biovitrum (Sobi) receives FDA approval for Elocta to treat Hemophilia A
Flamel Technologies receives FDA approval for Vazculep to treat hypotension caused by vasodilation under anesthesia.
Cutera receives FDA approval for enlighten™ to treat benign pigmented lesions
InterMune receives FDA approval for Esbriet to treat idiopathic pulmonary fibrosis
Flamel Technologies receives FDA approval for Akovaz to treat hypotension related to anesthesia.
Launch of Alta Partners NextGen Fund I
CoTherix receives FDA approval for Tracleer to treat pulmonary arterial hypertension
Kite Pharma receives FDA approval for Yescarta to treat large B-Cell Lymphoma.
Aerie Pharmaceuticals receives FDA approval for Rhopress to treat glaucoma
Launch of Alta Partners NextGen Fund II
Vir Biotechnologies completes initial public offering (NASDAQ: VIR)
Aerie Pharmaceuticals receives FDA approval for Rocklatan to treat glaucoma
Cutera receives FDA approval for Secret RF microneedling system to treat skin-related conditions
FoldRx Pharmaceuticals receives FDA approval for Vyndamax and Vyndaqel to treat cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM)
Esperion Therapeutics receives FDA approval for Nexletol and Nexlizet to treat hypercholesterolemia
Launch of Alta Partners NextGen Fund III
Tyra Biosciences, Inc. completes initial public offering (NASDAQ: TYRA)
Chimerix Receives FDA Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
TransMedics Receives FDA Approval for its OCS Heart System
Vir Biotechnology receives Emergency Use Authorization from the US FDA for sotrovimab (VIR-7831) to treat mild-to-moderate COVID-19 in high-risk adults and pediatric patients.
Bioventus Receives FDA 510(k) Clearance for its StimRouter Pain Management Device in March and its SonaStar Elite in August.
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication
